Process development and scale-up of pluripotent stem cell manufacturing

Cell & Gene Therapy Insights 2021; 7(12), 1657

10.18609/cgti.2021.219

Published: 16 December 2021
FastFacts
Gary M Pigeau PhD

Watch the video or read the poster to learn:

  • Scalable stirred-tank reactor train for pluripotent stem cell expansion improves the scale and process of cell therapy manufacturing
  • High-density seed banks can help remove manual manipulation steps, shorten expansion time by 50%, and decouple subsequent suspension differentiation
  • The potential for process correlations of viable cell densities to remove sampling and reduce labor costs and contamination risk

Gary Pigeau received his PhD in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta, with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined Cytiva and the Centre for Advanced Therapeutic Cell Technologies (CATCT) at CCRM in 2016. He serves as Director of the collaborative facility in Toronto, with a focus on biology support for new product introductions, internal technology development projects, and contract process development services in cell and gene therapy.